Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
Copyright policy )Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata
Alopecia areata (AA) is a common autoimmune disorder. Although its pathogenesis is not fully understood, AA involves CD8 T cell-mediated destruction of the hair follicle. Several treatment options exist; however, there is minimal evidence in the pediatric population. Currently, there are no curative treatments for AA. The literature suggests that Janus kinase (JAK) inhibitors may be an effective treat-ment for AA, but evidence in pediatric patients is limited. Here, we report a case of severe pediatric AA treated with topical ruxolitinib, a JAK inhibitor. J Drugs Dermatol. 2024;23(5):378-379. doi:10.36849/JDD.7782.
Pyrimidines, Treatment Outcome, Alopecia Areata, Nitriles, Skin Cream, Humans, Janus Kinase Inhibitors, Pyrazoles, Child, Administration, Cutaneous
Pyrimidines, Treatment Outcome, Alopecia Areata, Nitriles, Skin Cream, Humans, Janus Kinase Inhibitors, Pyrazoles, Child, Administration, Cutaneous
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!